Abstract:Background: Diabetes has been found to increase severity and mortality under the current pandemic of coronavirus disease of 2019 (COVID-19). Up to date, the clinical characteristics of diabetes patients with COVID-19 and the risk factors for poor clinical outcomes are not clearly understood.Methods: The study was retrospectively carried out on enrolled diabetes patients with laboratory confirmed COVID-19 infection from a designated medical center for COVID-19 from January 25th, 2020 to February 14th, 2020 in Wuhan, China. The medical record was collected and reviewed. Univariate and multivariate analyses were performed to assess the risk factors associated with the severe events which were defined as a composite endpoint of admission to intensive care unit, the use of mechanical ventilation, or death.Results: A total of 52 diabetes patients with COVID-19 were finally included in the study. 21 (40.4%) patients had developed severe events in 27.50 (IQR 12.25–35.75) days follow-up, 15 (28.8%) patients experienced life-threatening complications and 8 patients died with a recorded mortality rate of 15.4%. Only 13 patients (41.9%) were in optimal glycemic control with HbA1c value of <7.0%. In addition to general clinical characteristics of COVID-19, the severe events diabetes patients showed higher counts of white blood cells and neutrophil, lower lymphocytes (40, 76.9%), high levels of hs-CRP, erythrocyte sedimentation rate (ESR) and procalcitonin (PCT) as compared to the non-severe diabetes patients. Mild higher level of cardiac troponin I (cTNI) (32.0 pg/ml; IQR 16.80–55.00) and D-dimer (1.70 μg/L, IQR 0.70–2.40) were found in diabetes patients with severe events as compared to the non-severe patients (cTNI:20.00 pg/ml, IQR5.38–30.00, p = 0.019; D-dimer: 0.70 μg/L, IQR 0.30–2.40, p = 0.037). After adjusting age and sex, increased level of cTNI was found to significantly associate with the incidence of severe events (HR: 1.007; 95% CI: 1.000–1.013; p = 0.048), Furthermore, using of α-glucosidase inhibitors was found to be the potential protectant for severe events (HR: 0.227; 95% CI: 0.057–0.904; p = 0.035).Conclusion: Diabetes patients with COVID-19 showed poor clinical outcomes. Vigorous monitoring of cTNI should be recommended for the diabetes patients with COVID-19. Usage of α-glucosidase inhibitors could be a potential protectant for the diabetes patients with COVID-19.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the risk factors for severe clinical events in diabetic patients after being infected with COVID - 19. Specifically, the study aims to describe the clinical characteristics of diabetic patients co - infected with COVID - 19 and investigate the risk factors affecting the prognosis of these patients, especially the potential impact of different hypoglycemic drugs on the clinical course of COVID - 19 patients. Through a single - center retrospective cohort study, researchers hope to identify which factors may lead to an increased risk of developing severe illness or death in diabetic patients after being infected with COVID - 19. ### Research Background - **Research Objectives**: To explore the clinical characteristics of diabetic patients after being infected with COVID - 19 and the risk factors affecting their prognosis. - **Research Significance**: Diabetic patients are more likely to experience severe clinical events, such as admission to the intensive care unit (ICU), use of mechanical ventilation or death, after being infected with COVID - 19. However, the specific factors and mechanisms of these risks are still unclear. ### Main Findings - **Patient Characteristics**: The study included 52 diabetic patients with COVID - 19, among which 40.4% of the patients had severe clinical events, 23.1% of the patients were sent to the ICU, 28.8% of the patients experienced life - threatening complications, and 8 patients eventually died, with a mortality rate of 15.4%. - **Risk Factors**: - **Univariate Analysis**: White blood cell count, neutrophil count, lactate dehydrogenase level, creatine kinase level, high - sensitivity C - reactive protein level, erythrocyte sedimentation rate, interleukin - 6 level, and the use of α - glucosidase inhibitors (α - GI) were all significantly associated with severe events. - **Multivariate Analysis**: After adjusting for age and gender, an elevated cardiac troponin I (cTnI) level was significantly associated with the occurrence of severe events (HR = 1.007; 95% CI: 1.000–1.013; p = 0.048). Patients using α - glucosidase inhibitors had a 72% reduced risk of severe clinical events (HR: 0.227; 95% CI: 0.057–0.904; p = 0.035). ### Conclusions - **Clinical Recommendations**: For diabetic patients with COVID - 19, the cardiac troponin I (cTnI) level should be closely monitored. The use of α - glucosidase inhibitors may help reduce the risk of severe clinical events in these patients. ### Keywords - SARS - CoV - 2, COVID - 19, diabetes, risk factors, severe clinical events ### Formulas - **Hazard Ratio (HR)**: Used to assess the strength of the association between a factor and the occurrence of a severe event. For example, for every 1 - unit increase in cTnI level, the risk of a severe event increases by 1.007 times (HR = 1.007; 95% CI: 1.000–1.013; p = 0.048). - **95% Confidence Interval (95% CI)**: Represents the range of uncertainty of the estimate. For example, the 95% CI of cTnI is 1.000–1.013, indicating a high credibility of this estimate. It is hoped that this information will help you better understand the main content and conclusions of this study. If you have any further questions or need more detailed explanations, please feel free to let me know.

Risk Factors for Poor Outcomes of Diabetes Patients With COVID-19: A Single-Center, Retrospective Study in Early Outbreak in China

Risk Factors in Patients with Diabetes Hospitalized for COVID-19: Findings from a Multicenter Retrospective Study

Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: A retrospective study

Prevalence and Impact of Diabetes in Patients with COVID-19 in China

The risk factors for mortality of diabetic patients with severe COVID-19: A retrospective study of 167 severe COVID-19 cases in Wuhan

Clinical characteristics and outcomes of coronavirus disease 2019 infections among diabetics: A retrospective and multicenter study in China

Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication

Impaired Fasting Glucose and Diabetes Are Related to Higher Risks of Complications and Mortality Among Patients With Coronavirus Disease 2019

Retrospective study of the impact of diabetes on the severity and prognosis of COVID‑19

The association of diabetes and the prognosis of COVID-19 patients: A retrospective study

Association Between Diabetes and COVID-19: A Retrospective Observational Study With a Large Sample of 1,880 Cases in Leishenshan Hospital, Wuhan

Clinical Findings in Diabetes Mellitus Patients with COVID-19

Hyperglycemia is a strong predictor of poor prognosis in COVID-19

Clinical characteristics and acute complication of COVID-19 patients with diabetes: a multicenter, retrospective study in Southern China

Hyperglycemia and blood glucose deterioration are risk factors for severe COVID‐19 with diabetes: A two‐center cohort study

High Fasting Blood Glucose Level With Unknown Prior History of Diabetes Is Associated With High Risk of Severe Adverse COVID-19 Outcome

Diabetes, Even Newly Defined by HbA1c Testing, is Associated with an Increased Risk of In-Hospital Death in Adults with COVID-19

Diabetes Mellitus is Associated with Severe Infection and Mortality in Patients with COVID-19: A Systematic Review and Meta-analysis

Comorbid Diabetes and the Risk of Disease Severity or Death among 8807 COVID-19 Patients in China: A Meta-Analysis.

Major Characteristics of Severity and Mortality in Diabetic Patients With COVID-19 and Establishment of Severity Risk Score

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes